ARCUTIS BIOTHERAPEUTICS, INC. Accrued Liabilities, Current
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) had Accrued Liabilities, Current of $146.79 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-05
- 2026-06-30: Accrued Liabilities, Current $146.79M.
- 2026-03-31: Accrued Liabilities, Current $136.96M.
- 2025-12-31: Accrued Liabilities, Current $116.31M.
- 2025-09-30: Accrued Liabilities, Current $92.97M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $146.79M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $136.96M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $116.31M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $92.97M 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $87.85M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $65.76M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $66.79M 10-K · filed 2026-02-25 | $65.97M 10-K · filed 2025-02-25 |
| 2024-09-30 | $52.79M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $42.63M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $33.58M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $33.94M 10-K · filed 2025-02-25 | |
| 2023-09-30 | $28.00M 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $18.81M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $23.86M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $28.32M 10-K · filed 2024-02-27 | |
| 2022-09-30 | $27.80M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $18.46M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $19.99M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $25.54M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $13.88M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $10.56M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $12.17M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $15.46M 10-K · filed 2022-02-22 | |
| 2020-09-30 | $16.08M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $10.95M 10-Q · filed 2020-08-11 | |
| 2020-03-31 | $7.28M 10-Q · filed 2020-05-12 | |
| 2019-12-31 | $3.65M 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |